(Q39063083)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

title

Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Marc Humbert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Parameswaran Nair

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

R Buhl

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

A A Cruz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

H Inoue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

S Korom

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

N A Hanania

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

1 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

Clinical & Experimental Allergy

4 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

page(s)

161-175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

A summary of the new GINA strategy: a roadmap to asthma control

4 April 2020

cites work

1 reference

Asthma: defining of the persistent adult phenotypes

21 January 2018

1 reference

Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome

21 January 2018

1 reference

Severe asthma: from characteristics to phenotypes to endotypes

21 January 2018

1 reference

Stability of inflammatory phenotypes in asthma.

21 January 2018

1 reference

Asthma heterogeneity and severity-why is comprehensive phenotyping important?

21 January 2018

1 reference

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

21 January 2018

1 reference

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

21 January 2018

1 reference

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences

21 January 2018

1 reference

Noneosinophilic asthma: a distinct clinical and pathologic phenotype

21 January 2018

1 reference

Eosinophilic bronchitis: clinical manifestations and implications for treatment

21 January 2018

1 reference

Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma

21 January 2018

1 reference

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

21 January 2018

1 reference

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids

21 January 2018

1 reference

Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma

21 January 2018

1 reference

Therapeutic implications of 'neutrophilic asthma'.

21 January 2018

1 reference

Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β.

21 January 2018

1 reference

Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma.

21 January 2018

1 reference

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Glucocortiosteroid subsensitivity and asthma severity.

21 January 2018

1 reference

Type 2 inflammation in asthma--present in most, absent in many

21 January 2018

1 reference

Type 1/Type 2 immunity in infectious diseases

21 January 2018

1 reference

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells

21 January 2018

1 reference

Type-2 innate lymphoid cells in human allergic disease

21 January 2018

1 reference

Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33.

21 January 2018

1 reference

TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation

21 January 2018

1 reference

IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy.

21 January 2018

1 reference

Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop

21 January 2018

1 reference

Th17 cells: new players in asthma pathogenesis

21 January 2018

1 reference

IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways

21 January 2018

1 reference

Insights into the initiation of type 2 immune responses

21 January 2018

1 reference

In vivo studies fail to reveal a role for IL-4 or STAT6 signaling in Th2 lymphocyte differentiation

21 January 2018

1 reference

Interleukin-13 signaling and its role in asthma

21 January 2018

1 reference

Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.

21 January 2018

1 reference

Type 2 innate lymphoid cells: at the cross-roads in allergic asthma

21 January 2018

1 reference

Unique maturation program of the IgE response in vivo

21 January 2018

1 reference

Targeting interleukins to treat severe asthma

21 January 2018

1 reference

Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma

21 January 2018

1 reference

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

21 January 2018

1 reference

Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain

21 January 2018

1 reference

Asthma: mechanisms of disease persistence and progression

21 January 2018

1 reference

IL-13 receptors and signaling pathways: An evolving web

21 January 2018

1 reference

Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice?

21 January 2018

1 reference

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

21 January 2018

1 reference

Role of Th2 responses in the development of allergen-induced airway remodelling in a murine model of allergic asthma

21 January 2018

1 reference

Requirement for IL-13 independently of IL-4 in experimental asthma

21 January 2018

1 reference

IL-13 receptor α2 contributes to development of experimental allergic asthma

21 January 2018

1 reference

IL-4/IL-13 signaling beyond JAK/STAT

21 January 2018

1 reference

IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle

21 January 2018

1 reference

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

21 January 2018

1 reference

Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells

21 January 2018

1 reference

Eosinophil trafficking in allergy and asthma.

21 January 2018

1 reference

Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation.

21 January 2018

1 reference

Interleukin-5 and IL-5 receptor in health and diseases

21 January 2018

1 reference

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

21 January 2018

1 reference

The biological role of interleukin 5.

21 January 2018

1 reference

Regulation of bone marrow and airway CD34+ eosinophils by interleukin-5.

21 January 2018

1 reference

Eosinophil trafficking in asthma

21 January 2018

1 reference

IL-5- and eosinophil-mediated inflammation: from discovery to therapy

21 January 2018

1 reference

Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma

21 January 2018

1 reference

Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model.

21 January 2018

1 reference

IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways

21 January 2018

1 reference

IL-13 Mediates In Vivo IL-9 Activities on Lung Epithelial Cells but Not on Hematopoietic Cells

21 January 2018

1 reference

Serum periostin: a novel biomarker for asthma management

21 January 2018

1 reference

21 January 2018

Adult asthma biomarkers

1 reference

An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications

21 January 2018

1 reference

An airway epithelial iNOS-DUOX2-thyroid peroxidase metabolome drives Th1/Th2 nitrative stress in human severe asthma

21 January 2018

1 reference

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.

21 January 2018

1 reference

Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study

21 January 2018

1 reference

Biomarkers of therapy responsiveness in asthma: pitfalls and promises

21 January 2018

1 reference

Clinical update on the use of biomarkers of airway inflammation in the management of asthma

21 January 2018

1 reference

What is an "eosinophilic phenotype" of asthma?

21 January 2018

1 reference

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation

21 January 2018

1 reference

Exacerbations of asthma without sputum eosinophilia

21 January 2018

1 reference

Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations

21 January 2018

1 reference

Therapeutic strategies to reduce asthma exacerbations

21 January 2018

1 reference

The course of persistent airflow limitation in subjects with and without asthma

21 January 2018

1 reference

Factors associated with persistent airflow limitation in severe asthma

21 January 2018

1 reference

Immunological basis of reversible and fixed airways disease

21 January 2018

1 reference

Eosinophilic inflammation in allergic asthma.

21 January 2018

1 reference

Importance of concomitant local and systemic eosinophilia in uncontrolled asthma.

21 January 2018

1 reference

High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma.

21 January 2018

1 reference

Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects

21 January 2018

1 reference

External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma.

21 January 2018

1 reference

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

21 January 2018

1 reference

Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma

21 January 2018

1 reference

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses

21 January 2018

1 reference

Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation

21 January 2018

1 reference

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

21 January 2018

1 reference

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

21 January 2018

1 reference

Human asthma phenotypes: from the clinic, to cytokines, and back again

21 January 2018

1 reference

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

21 January 2018

1 reference

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

21 January 2018

1 reference

Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes

21 January 2018

1 reference

TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice

21 January 2018

1 reference

An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells

21 January 2018

1 reference

T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma.

21 January 2018

1 reference

Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD.

21 January 2018

1 reference

Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

21 January 2018

1 reference

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma.

21 January 2018

1 reference

Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies

21 January 2018

1 reference

Full blood count parameters for the detection of asthma inflammatory phenotypes.

21 January 2018

1 reference

A chitinase-like protein in the lung and circulation of patients with severe asthma

21 January 2018

1 reference

The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma

21 January 2018

1 reference

The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children

21 January 2018

1 reference

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

21 January 2018

1 reference

Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4.

21 January 2018

1 reference

Antibiotics for preschool wheeze.

21 January 2018

1 reference

Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Phenotype-specific treatment of difficult asthma in children

21 January 2018

1 reference

Infection and inflammation in induced sputum from preschool children with chronic airways diseases

21 January 2018

1 reference

Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma.

21 January 2018

1 reference

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma

21 January 2018

1 reference

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma.

21 January 2018

1 reference

Periostin is required for maximal airways inflammation and hyperresponsiveness in mice.

21 January 2018

1 reference

Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways

21 January 2018

1 reference

Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness.

21 January 2018

1 reference

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.

21 January 2018

1 reference

Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy

21 January 2018

1 reference

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

21 January 2018

1 reference

External validity of trials should be taken into account before asthma drug candidates reach market authorisation.

21 January 2018

1 reference

Adaptive Designs for Clinical Trials

21 January 2018

1 reference

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

21 January 2018

1 reference

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

21 January 2018

1 reference

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.

21 January 2018

1 reference

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts

21 January 2018

1 reference

Mepolizumab treatment in patients with severe eosinophilic asthma.

21 January 2018

1 reference

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

21 January 2018

1 reference

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

21 January 2018

1 reference

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

21 January 2018

1 reference

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

21 January 2018

1 reference

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/CEA.12880

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28036144%20AND%20SRC:MED&resulttype=core&format=json

release_uufp7yx4erarzllz6drnq4ihx4

4 April 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uufp7yx4erarzllz6drnq4ihx4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference